Gastrointestinal infectious disease
Vedanta Biosciences Inc. is active in clinical research on Clostridioides difficile infection, with a focus on preventing recurrence and addressing the disruption of the intestinal microbial ecosystem associated with this condition.
- Recurrent Clostridioides difficile infection
- Gut microbiome restoration
- Infectious diarrhoeal disease
The sponsor’s work in this area is centered on therapies designed for patients at risk of repeated infection and ongoing gastrointestinal complications.
Inflammatory bowel disease
The company also funds research in mild-to-moderate ulcerative colitis, a chronic inflammatory bowel disease marked by mucosal inflammation and impaired intestinal function.
- Ulcerative colitis
- Colonic inflammation
- Endoscopic response
This therapeutic area reflects interest in improving disease control in patients with active colitis and persistent gastrointestinal symptoms.
Microbiome-based therapeutics
Vedanta Biosciences Inc. focuses on microbiome-based therapy approaches that target the intestinal microbial community as a way to influence disease activity in both infectious and inflammatory settings.
- Live biotherapeutic products
- Microbial consortia
- Intestinal ecosystem modulation
Its clinical portfolio places the gastrointestinal microbiota at the center of therapeutic development.
Clinical gastroenterology
The sponsor’s trials are concentrated in gastroenterology, with research sites spread across multiple countries and a strong emphasis on conditions affecting the colon and lower gastrointestinal tract.
- Colonic disease
- Intestinal inflammation
- Lower gastrointestinal disorders
This includes clinical evaluation in patients with recurrent infection and chronic inflammatory bowel disease.
